Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.2K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.6K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

3.2K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.2K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

829
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
829

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Electroencephalographic manifestations of intracranial hypertension in a patient with ventriculoperitoneal shunt malfunction.

Seizure·2025
Same author

Radiologic findings in women after Autologous Fat Transfer (AFT) based breast reconstruction: A Systematic Review.

JPRAS open·2024
Same author

Cu-based thin rolled foils: relationship among alloy composition, micromechanical and antiviral properties against SARS-CoV-2.

Heliyon·2024
Same author

Mesoglycan for the secondary prevention of superficial vein thrombosis: a randomized, controlled, double-blind study (METRO Study)-rationale and protocol.

Journal of thrombosis and thrombolysis·2023
Same author

Polyaniline/poly (2-acrylamido-2-methyl-1-propanesulfonic acid) modified cellulose as promising material for sensors design.

Carbohydrate polymers·2023
Same author

Absence of interaction between rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation.

Vascular pharmacology·2020

Related Experiment Video

Updated: May 6, 2026

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation
08:48

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation

Published on: January 26, 2016

11.5K

New antitumoral cyclopeptides.

E Bernardi1, J L Fauchère, G Atassi

  • 1URA-CNRSn°468, Université Montpellier II, Place E. Bataillon, F-34095, Montpellier Cedex 5, France.

Amino Acids
|November 6, 2013
PubMed
Summary
This summary is machine-generated.

Researchers developed novel cyclic tetrapeptides with potent antitumoral activity. One analog showed significant promise against murine leukemia, outperforming a standard chemotherapy drug in vivo.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

10.9K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

10.8K

Related Experiment Videos

Last Updated: May 6, 2026

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation
08:48

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation

Published on: January 26, 2016

11.5K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

10.9K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

10.8K

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Oncology

Background:

  • Chlamydocin is an effective in vitro antitumoral agent but is rapidly inactivated in vivo.
  • Cyclic tetrapeptides, including chlamydocin and HC toxin, are known for their biological activities.
  • Developing agents with improved in vivo stability and efficacy is crucial for cancer therapy.

Purpose of the Study:

  • To synthesize and evaluate novel cyclic tetrapeptide analogs of chlamydocin.
  • To investigate the antitumoral activity of these analogs against L1210 and P388 murine leukemia cell lines.
  • To compare the efficacy and therapeutic index of the most potent analog with a standard chemotherapy drug.

Main Methods:

  • Synthesis of cyclic tetrapeptide analogs incorporating a bioactive alkylating group on a lysyl function.
  • In vitro assessment of cytotoxicity and proliferation inhibition on L1210 and P388 leukemia cells.
  • In vivo evaluation of antileukemic activity and therapeutic index in a P388-induced leukemia mouse model.

Main Results:

  • One synthesized analog demonstrated potent inhibition of L1210 cell proliferation in vitro.
  • This analog exhibited significant antileukemic activity in the P388-induced leukemia model in vivo.
  • The analog displayed a higher therapeutic index compared to bis-β-chloroethylnitrosourea (BCNU) in the in vivo model.

Conclusions:

  • Novel cyclic tetrapeptide analogs can be designed to overcome the in vivo inactivation limitations of agents like chlamydocin.
  • The most potent analog represents a promising new candidate for further development as an antileukemic agent.
  • This research highlights the potential of modifying peptide structures to enhance anticancer drug efficacy and safety.